The tumor suppressor BRCA2 plays a key role in genome integrity by promoting replication-fork stability and homologous recombination (HR) DNA repair. Here we report that human cancer cells lacking BRCA2 rely on the Fanconi anemia protein FANCD2 to limit replication-fork progression and genomic instability. Our results identify a new role of FANCD2 in limiting constitutive replication stress in BRCA2-deficient cells, thereby affecting cell survival and treatment responses.
Mutations in breast cancer susceptibility gene 2 (BRCA2) predispose individuals to breast and ovarian cancer. As a result of compromised HR repair, BRCA2-mutated tumor cells differ from normal cells in their responses to exogenous DNA damage and to endogenous challenges that arise during DNA replication (for example, at telomeres) 1,2 . These differences are due to the essential function of BRCA2 in protecting stalled replication forks against nucleolytic degradation 3, 4 . A similar role in DNA replication has been ascribed to the Fanconi anemia group D2 protein (FANCD2) 5 . FANCD2 is a central component of the Fanconi anemia pathway for DNA cross-link repair, and its inactivation is associated with progressive bone-marrow failure and cancer predisposition.
Recent work has demonstrated that FANCD2 regulates responses to replication stress induced by mitomycin C and hydroxyurea (HU) [5] [6] [7] . BRCA2 abrogation likewise triggers replication stress, a hallmark of BRCA2-deficient cancer cells that drives the associated pathologies 8 . Hence, we sought to investigate whether FANCD2 mediates replication-stress responses in cells lacking BRCA2 and how this mediation might contribute to the genome integrity and survival of these cells.
FANCD2 and BRCA2 are both required to prevent MRE11dependent degradation of nascent DNA at stalled replication forks 3, 5 . However, whether the two factors functionally interact with each other during this process has not been addressed. To investigate fork protection in cells lacking both FANCD2 and BRCA2, we transfected short interfering RNA (siRNA) against FANCD2 into H1299 cells stably expressing doxycycline (Dox)-inducible short hairpin RNA (shRNA) against BRCA2 (Fig. 1a) . We monitored replication-fork degradation after prolonged HU treatment by using DNA fiber analyses (Fig. 1b) . Consistently with the previously described roles of FANCD2 and BRCA2 in the protection of replication forks 3, 5 , DNA tracks were significantly shorter in FANCD2-or BRCA2-depleted cells. Importantly, concomitant depletion of FANCD2 and BRCA2 resulted in increased levels of fork degradation, thus indicating that the two proteins mediated the protection of stalled forks by distinct mechanisms. Inhibition of MRE11 nuclease activity with mirin partially rescued the degradation of nascent DNA in cells lacking FANCD2 and BRCA2, thus implicating MRE11 as one of the nucleases required for fork resection in this context.
Replication at stalled forks can be restarted by multiple mechanisms 9 . However, the roles of FANCD2 and BRCA2 in replicationfork restart remain controversial 3, 5, 10 . In cells lacking FANCD2 or BRCA2, we observed impaired replication restart after HU treatment ( Fig. 1c) . This defect was more pronounced in cells deficient in both proteins, thus suggesting that FANCD2 and BRCA2 play independent roles in restarting HU-arrested replication forks.
FANCD2 restricts DNA synthesis after HU-induced replication stress, thus preventing the accumulation of deleterious single-stranded-DNA gaps 7 . BRCA2-deficient cells exhibit high levels of endogenous replication stress 11 resembling that induced by HU treatment. To determine whether FANCD2 limits DNA synthesis under replicationstress conditions associated with BRCA2 inactivation, we measured replication rates in two BRCA2-deficient human cell lines treated with FANCD2 siRNA or control siRNA. In both cell lines, FANCD2 depletion increased the track length ( Fig. 1d-f and Supplementary Fig. 1a ), thus indicating that FANCD2 inhibits replication-fork progression in the absence of BRCA2. Additionally, we observed an increase in origin firing in BRCA2-deficient cells lacking FANCD2 ( Supplementary  Fig. 1b) , thus suggesting that FANCD2 suppresses the activation of origins and thereby prevents uncontrolled replication in the context of BRCA2 deficiency, similarly to HU 12 . Uncontrolled replication leads to accumulation of DNA damage 9 . Hence, in cells lacking FANCD2 and BRCA2, we observed enhanced levels of chromosomal aberrations (relative to single depletion, Fig. 1g,h) , as well as elevated levels of phosphorylated histone H2AX (γ-H2AX) foci ( Fig. 1i) , which mark DNA-damage sites. Thus, FANCD2 is required to prevent genomic instability in BRCA2-deficient cells.
DNA-damage accumulation triggers DNA-damage responses, ultimately leading to senescence and apoptosis 13 . To determine whether the genomic instability observed in cells lacking FANCD2 and BRCA2 affects cell fate, we assessed apoptosis and senescence by using Annexin V and β-galactosidase staining, respectively. We observed a significant increase in apoptotic, Annexin V-binding cells after concomitant abrogation of FANCD2 and BRCA2 expression in H1299 VOLUME 23 NUMBER 8 AUGUST 2016 nature structural & molecular biology b r i e F c o m m u n i c at i o n s cells, as compared with inhibition of each factor alone ( Fig. 2a) . Likewise, FANCD2and BRCA2-depleted primary MRC-5 human cells entered senescence at a higher rate than did cells lacking either FANCD2 or BRCA2 ( Supplementary Fig. 2 ), as measured through β-galactosidase staining.
Next, we investigated a potential synthetic lethality between FANCD2 and BRCA2. FANCD2 inhibition through two different siR-NAs significantly decreased survival of H1299, DLD1 and MDA-MB-231 cells lacking BRCA2 expression in clonogenic assays ( Fig. 2b-d and Supplementary Fig. 3a-d) . Consistently with this observation, survival of DLD1 cells, in which FANCD2 expression was abrogated through the CRISPR-Cas9 technique, was significantly decreased by siRNA-mediated depletion of BRCA2 ( Fig. 2e and Supplementary  Fig. 3e ). This result indicated that FANCD2 is required for survival of BRCA2-deficient cells and suggests a synthetic lethal interaction between the two genes 14 . Depletion of the Fanconi anemia corecomplex component FANCA led to significantly impaired survival of BRCA2-deficient cells ( Supplementary Fig. 3f ), thus indicating that ubiquitination of FANCD2 is required in cells lacking BRCA2.
Interestingly, cell lines and tumors carrying BRCA2 mutations exhibited higher FANCD2 mRNA expression levels than cell lines and tumors with wild-type BRCA2 (Fig. 2f, Supplementary Fig. 4 and Supplementary Tables 1 and 2) . Thus far, no functional assays have been carried out to establish whether these mutations result in loss of BRCA2 function. However, our findings raise the possibility that upregulated FANCD2 transcription promotes the survival of BRCA2-deficient cells and tumors.
BRCA2 deficiency is commonly targeted by chemical inhibition of poly(ADP-ribose) polymerase 1 (PARP1), whereas Fanconi anemia patient cell lines are generally not sensitive to PARP inhibitors 15 . To address whether FANCD2 modulates the response to PARP inhibition, we treated H1299 cells lacking FANCD2, BRCA2 or both with low doses of olaparib ( Fig. 2g) . Consistently with previous results 15 , this treatment was not toxic in the context of FANCD2 loss. However, we observed that FANCD2 abrogation enhanced the sensitivity of BRCA2-deficient cells to olaparib, thus suggesting that FANCD2 mediates mechanisms of resistance to this drug.
In summary, we demonstrated that FANCD2 is essential for cell survival in the absence of BRCA2. FANCD2 promotes DNA synthesis and replication-fork protection and restart in BRCA2-deficient cells. This role of FANCD2 is analogous to that previously reported in response to exogenously induced replication stress (for example, HU). FANCD2 provides a protection mechanism against genomic instability in cells lacking BRCA2, and its abrogation is lethal to these cells. Elevated apoptosis and decreased survival of BRCA2-compromised cells after FANCD2 abrogation could be exploited therapeutically by treating BRCA2-deficient tumors with FANCD2 inhibitors. 
ONLINe MeTHODs
Cell lines and culture conditions. Human non-small cell lung carcinoma H1299 cells, human embryonic kidney HEK-293T cells, human mammary gland MDA-MB-231 cells, primary human fibroblast MRC-5 cells (all from American Type Culture Collection) and colorectal adenocarcinoma DLD1 cells (parental and BRCA2 mutated, Horizon Discovery) were cultivated in monolayers in DMEM (Sigma-Aldrich) supplemented with 10% FBS (Life Technologies), 1% penicillin and streptomycin (Sigma-Aldrich). H1299 and MDA-MB-231 cells expressing Dox-inducible BRCA2 shRNA were established as previously described 1 . Cell lines were routinely tested for mycoplasma contamination. H1299 and DLD1 cell lines were authenticated in February 2016.
Generation of FANCD2 −/− cells by CRISPR-Cas9. FANCD2 double nickase plasmid (sc-400445-NIC) and FANCD2 homology-directed repair (HDR) plasmid (sc-400445-HDR) were purchased from Santa Cruz. DLD1 cells were transfected with 1 µg of each construct by using Lipofectamine 2000 (Thermo Fisher Scientific). The medium was replaced with antibiotic-free medium 24 h after transfection. After 24 h, puromycin (2 µg/ml) was added for 72 h to select cells expressing Cas9 nickase. Cells were left to recover for 6 d before being seeded for single-cell cloning. Clones showing loss of all detectable FANCD2 by immunoblotting were selected for subsequent analysis.
RNA interference. Cells were transfected with siRNA by reverse transfection with DharmaFECT 1 (Dharmacon). FANCD2 and BRCA2 siGENOME SMARTpool (used at 40 nM) were obtained from Dharmacon, FANCA and FANCD2 esiRNA (used at 20 nM) were obtained from Sigma-Aldrich, and AllStars negative-control siRNA was obtained from Qiagen.
Clonogenic survival assays. Cells were plated in triplicate at densities between 200 and 1,000 cells per well in six-well plates, and drug treatment was initiated after cells had adhered. After 24-h incubation with the drug, fresh medium without the drug was added, and cells continued to grow for 10-14 d. Colonies were stained with 0.5% crystal violet (Sigma Aldrich) in 50% methanol and 20% ethanol in dH 2 O. Cell survival was expressed relative to untreated cells of the same cell line.
b-galactosidase assay. Cells were fixed with 2% formaldehyde and 0.2% glutaraldehyde for 10-15 min at room temperature and stained by incubation with freshly prepared staining solution (1 mg/ml X-Gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl 2 and 40 mM citric acid, pH 6.0) at 37 °C under atmospheric CO 2 levels. Staining was stopped after 6 h. Cells were examined through light microscopy. The numbers of cells analyzed per sample from three independent experiments were: −Dox, −FANCD2, n = 2,342; −Dox, +FANCD2, n = 1,971; +Dox, −siFANCD2, n = 1,926; and +Dox, +siFANCD2, n = 2,330.
Annexin V assay. Apoptotic and dead cells were labeled with a FITC Annexin V/Dead Cell Apoptosis Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Stained cells were immediately analyzed by flow cytometry (FACSCalibur, BD Biosciences). Early apoptotic cells bound Annexin V-FITC but excluded propidium iodide (PI). Cells in necrotic or late apoptotic stages were labeled with both Annexin V-FITC and PI. 20,000 events were analyzed per condition and experiment with FlowJo software.
Immunofluorescence. Cells were washed in PBS, swollen in hypotonic solution (85.5 mM NaCl and 5 mM MgCl 2 ) for 5 min, fixed with 4% paraformaldehyde for 10 min at room temperature and permeabilized by addition of 0.03% SDS to the fixative. After blocking with blocking buffer (1% goat serum, 0.3% BSA and 0.005% Triton X-100 in PBS), cells were incubated with primary antibody diluted in blocking buffer overnight at room temperature. Then they were washed again and incubated with fluorochrome-conjugated secondary antibody for 1 h at room temperature (1:300, anti-mouse Alexa 546, A-11003, Molecular Probes). Dried coverslips were mounted on microscope slides with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Specimens were imaged with an LSM780 (Carl Zeiss Microscopy) confocal microscope, and nuclei were analyzed with ImageJ software (NIH). The numbers of nuclei analyzed per sample from four independent experiments were: −Dox, −siFANCD2, n = 767; −Dox, +siFANCD2, n = 668; +Dox, −siFANCD2, n = 737; and +Dox, +siFANCD2, n = 650.
Preparation of metaphase spreads. Mitotic cells were collected by mitotic shakeoff and swollen in hypotonic buffer (0.03 M sodium acetate) at 37 °C for 25 min, then fixed in a freshly prepared 3:1 mix of methanol/glacial acetic acid. Nuclear preparations were deposited onto slides presoaked in 45% acetic acid and stained with Giemsa. Metaphases were viewed with a Leica DMI6000B inverted microscope equipped with an HCX PL APO 100×/1.4-0.7 oil objective. Images were acquired with a Leica DFC350 FX R2 digital camera and LAS-AF software (Leica). Brightness levels and contrast adjustments were applied with Photoshop CS3 (Adobe). 60 metaphases from two independent experiments were quantified per condition.
DNA fiber assay. DNA was labeled with 25 µM CldU and 250 µM IdU, as outlined in the figures. HU was used at 2 mM, and mirin was used at 50 µM. The reaction was terminated by addition of ice-cold PBS. After cell lysis, DNA was spread on glass slides, fixed in methanol/acetic acid, denatured with HCl, blocked with 2% BSA and stained with anti-rat anti-CldU ( Antibodies. The following antibodies were used for immunoblotting: rabbit polyclonal antisera raised against FANCD2 (NB100-182, Novus Biologicals, validated in Lossaint, et al. 7 ) and SMC1 (A300-055A, Bethyl Laboratories, validated in Zimmer, et al. 1 ), and a mouse monoclonal antibody raised against BRCA2 (OP95, Merck Millipore, validated in Zimmer, et al. 1 ). The following secondary antibodies were used: polyclonal goat anti-rabbit immunoglobulins/HRP (P0448, Dako) and polyclonal goat anti-mouse immunoglobulin/HRP (P0447, Dako). A mouse monoclonal antibody raised against phosphorylated histone H2AX S139 (05-636, clone JBW301, Merck Millipore, validated in Zimmer, et al. 1 ) was used for immunofluorescence detection.
Genomic and transcriptional analysis in cell lines. Genomic data for a panel of 1,025 human cell lines were assembled from the COSMIC database 16 . Cell-line pellets collected during exponential growth in RPMI or DMEM/F12 were used to generate microarray data with the Human Genome U219 array (Affymetrix). The robust multiarray analysis algorithm 17 was used to establish intensity values for each of 18,562 loci (BrainArray v.10 (ref. 18)). The normalized data were then normalized gene-wise. Subsequently, the expression of each gene was centered across each tissue (0 mean and unitary s.d.). Raw data were from ArrayExpress E-MTAB-3610. Driver mutations in BRCA2 were defined as those that were truncating and therefore likely to result in a shortened translation product (frameshift, nonsense and essential splice mutations) or homozygous deletions at the copy-number level. These mutations were then correlated with FANCD2 gene expression.
FANCD2 mRNA expression levels in tumors. Data of 971 human breast cancer and normal matched samples were considered from The Cancer Genome Atlas 19 . Expression of FANCD2 mRNA was considered in samples with and without BRCA2 somatic mutations. The equality of expression distribution was tested with a Kruskal-Wallis rank-sum test (Kruskal-Wallis chi-squared = 10.043, df = 2, P = 0.006596). 
